Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Pharmacokinetics"
DOI: 10.1007/s40262-017-0623-4
Abstract: Telavancin was discovered by modifying the chemical structure of vancomycin and belongs to the group of lipoglycopeptides. It employs its antimicrobial potential through two distinct mechanisms of action: inhibition of bacterial cell wall synthesis and… read more here.
Keywords: clinical pharmacokinetics; telavancin; plasma; soft tissue ... See more keywords
Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations.
Sign Up to like & getrecommendations! Published in 2017 at "Diagnostic microbiology and infectious disease"
DOI: 10.1016/j.diagmicrobio.2017.03.003
Abstract: Telavancin was tested against a worldwide collection of Gram-positive pathogens (967) isolated from bone and joint infections (BJI). Most BJI isolates were from the United States (US) (49.9%) followed by Europe (26.4%), Latin America (LATAM;… read more here.
Keywords: gram positive; telavancin; isolated bone; joint infections ... See more keywords
Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients
Sign Up to like & getrecommendations! Published in 2018 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.00956-18
Abstract: Methicillin-resistant Staphylococcus aureus (MRSA) acquisition in cystic fibrosis (CF) patients confers a clinical outcome worse than that in non-CF patients with an increased rate of declined lung function. Telavancin, an approved lipoglycopeptide used to treat… read more here.
Keywords: telavancin; staphylococcus aureus; cystic fibrosis; fibrosis patients ... See more keywords
Efficacy of Telavancin in Comparison to Linezolid in a Porcine Model of Severe Methicillin-Resistant Staphylococcus aureus Pneumonia
Sign Up to like & getrecommendations! Published in 2020 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01009-20
Abstract: Current guidelines recommend vancomycin and linezolid as first-line agents against methicillin-resistant Staphylococcus aureus (MRSA) nosocomial pneumonia. Telavancin is a potential new therapeutic alternative, specifically in monomicrobial MRSA pneumonia. This study compared the efficacies of telavancin… read more here.
Keywords: telavancin; porcine model; pneumonia; model severe ... See more keywords